Session » (2326–2351) SLE – Treatment Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2329

AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo

9:00AM-11:00AM: Abstract Number: 2332

Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 2333

Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial

9:00AM-11:00AM: Abstract Number: 2335

Defining a Basket Population for ANA+ Arthritis Trials

9:00AM-11:00AM: Abstract Number: 2328

Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial

9:00AM-11:00AM: Abstract Number: 2330

Disease-Related Outcomes of Cognitive Behavioral Therapy in Randomized Control Trial for Youth with Childhood-onset SLE: A Secondary Analysis

9:00AM-11:00AM: Abstract Number: 2326

Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g

9:00AM-11:00AM: Abstract Number: 2347

Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials

9:00AM-11:00AM: Abstract Number: 2339

Fragility of Randomized Clinical Trials of Systemic Lupus Erythematosus and Lupus Nephritis Therapies

9:00AM-11:00AM: Abstract Number: 2351

Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years

9:00AM-11:00AM: Abstract Number: 2343

Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications

9:00AM-11:00AM: Abstract Number: 2327

Hydroxychloroquine Improves Low Complement Levels

9:00AM-11:00AM: Abstract Number: 2336

Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis

9:00AM-11:00AM: Abstract Number: 2348

Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

9:00AM-11:00AM: Abstract Number: 2342

Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial

9:00AM-11:00AM: Abstract Number: 2331

Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2340

Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 2345

Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2334

Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period

9:00AM-11:00AM: Abstract Number: 2338

Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2337

Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 2349

Selection of the Dose for Subcutaneous Administration to Non-Japanese Subjects and Intravenous Administration to Japanese Subjects in the First-in-Human Study of DS-7011a, an Anti-TLR7 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2346

SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

9:00AM-11:00AM: Abstract Number: 2341

Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2344

Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study

9:00AM-11:00AM: Abstract Number: 2350

Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303; TACI vTD-Fc)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].